AAG
NTLA icon

Armstrong Advisory Group’s Intellia Therapeutics NTLA Stock Holding History

Armstrong Advisory Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-144
Closed -$1.29K – 986
2025
Q4 		$1.29K Hold
144
– – ﹤0.01% 896
2025
Q3 		$2.49K Buy
+144
New +$1.77K ﹤0.01% 836

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Armstrong Advisory Group's NTLA Position: Q1 2026 in Review

Armstrong Advisory Group sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 144 shares — an estimated $1.29K sold.

Armstrong Advisory Group first reported a position in NTLA in Q3 2025 and held it in 2 quarters. The position peaked at $2.49K in Q3 2025. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Armstrong Advisory Group reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Armstrong Advisory Group sold 144 Intellia Therapeutics shares in Q1 2026, an estimated $1.29K.
  • Armstrong Advisory Group first reported a position in Intellia Therapeutics in Q3 2025 and held it in 2 quarters.
  • Armstrong Advisory Group's Intellia Therapeutics position peaked at $2.49K in Q3 2025.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Armstrong Advisory Group's 13F filing for Q1 2026, filed 10 Apr 2026.